2
Clinical Trials associated with PEPIDH1M vaccine(Duke University)ViCToRy: Vorasidenib in Combination with Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
The purpose of this study is to determine the safety and efficacy of a PEPIDH1M vaccine in combination with vorasidenib, a dual inhibitor of mutant IDH1 and IDH2 enzymes, in adult patients diagnosed with recurrent IDH1 mutant lower grade gliomas.
Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine
Potential subjects with progressive Grade II primary brain tumor that have IDH1 positive testing from the primary tumor (initial diagnosis) will be offered this treatment study in order to test the safety of the PEPIDH1M vaccine in combination with standard chemotherapy (temozolomide).
100 Clinical Results associated with PEPIDH1M vaccine(Duke University)
100 Translational Medicine associated with PEPIDH1M vaccine(Duke University)
100 Patents (Medical) associated with PEPIDH1M vaccine(Duke University)
100 Deals associated with PEPIDH1M vaccine(Duke University)